RAISE

NCT01183780 📎

Regimen

Experimental
Ramucirumab 8 mg/kg Q2W + FOLFIRI
Control
Placebo + FOLFIRI

Population

Metastatic CRC, 2L, after progression on first-line bevacizumab + oxaliplatin-containing regimen.

Key finding

2L mCRC (post-bev+oxaliplatin+fluoropyrimidine 1L): mOS 13.3 vs 11.7 mo (HR 0.844, 95% CI 0.730-0.976, p=0.0219); mPFS 5.7 vs 4.5 mo (HR 0.793, p=0.0005); consistent benefit across subgroups; grade 3+ neutropenia 38% vs 23%

Source: PMID 25877855

Timeline

    Guideline citations

    • NCCN Colon (p.20)
    • NCCN Rectal (p.26)